- Home
- SATL vs PRTC Comparison
SATL vs PRTC Comparison
Compare SATL & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SATL | PRTC |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 482.3M | 464.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SATL | PRTC |
|---|---|---|
| Price | $5.71 | $15.24 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $5.50 | N/A |
| AVG Volume (30 Days) | ★ 9.5M | 3.8K |
| Earning Date | 05-12-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $68.54 | N/A |
| Revenue Next Year | $56.23 | N/A |
| P/E Ratio | ★ N/A | $8.09 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.26 | $13.30 |
| 52 Week High | $6.84 | $20.00 |
Technical Indicators
Market Signals| Indicator | SATL | PRTC |
|---|---|---|
| Relative Strength Index (RSI) | 64.95 | 34.78 |
| Support Level | $3.18 | $14.50 |
| Resistance Level | $5.93 | $17.98 |
| Average True Range (ATR) | 0.75 | 0.37 |
| MACD | 0.20 | -0.12 |
| Stochastic Oscillator | 71.12 | 20.24 |
Price Performance
Historical ComparisonAbout SATL Satellogic Inc.
Satellogic Inc is a provider of satellite imagery to governments and commercial customers globally. It geographically operates in North America, Europe, Asia and South America. It derives maximum revenue from Asia Pacific.
About PRTC PureTech Health plc
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.